Lumryz

News

Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

News

Alkermes will buy Avadel Pharma and its fast-growing narcolepsy drug Lumryz in a deal valued at up to $2.1 billion.

News

BioMarin will acquire Alesta's experimental therapy for rare bone disease hypophosphatasia for up to $490 million.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.